In Vitro Antifungal Activity of Isavuconazole against Madurella mycetomatis
Open Access
- 1 November 2012
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 56 (11) , 6054-6056
- https://doi.org/10.1128/aac.01170-12
Abstract
Currently, therapy of black-grain mycetoma caused by Madurella mycetomatis consists of extensive debridement of the infected tissue combined with prolonged antifungal therapy with ketoconazole or itraconazole. In the present study, the in vitro activity of the new triazole isavuconazole toward M. mycetomatis was evaluated. Isavuconazole appeared to have high activity against M. mycetomatis, with MICs ranging from ≤0.016 to 0.125 μg/ml. Due to its favorable pharmacokinetics, isavuconazole could be a promising antifungal agent in the treatment of mycetoma.Keywords
This publication has 26 references indexed in Scilit:
- Species-Specific Antifungal Susceptibility Patterns of Scedosporium and Pseudallescheria SpeciesAntimicrobial Agents and Chemotherapy, 2012
- In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility TestingDiagnostic Microbiology and Infectious Disease, 2011
- In Vitro Susceptibility of Madurella mycetomatis to Posaconazole and TerbinafineAntimicrobial Agents and Chemotherapy, 2011
- In Vitro Antifungal Susceptibilities and Amplified Fragment Length Polymorphism Genotyping of a Worldwide Collection of 350 Clinical, Veterinary, and Environmental Cryptococcus gattii IsolatesAntimicrobial Agents and Chemotherapy, 2010
- In Vitro Activities of Eight Antifungal Drugs against 55 Clinical Isolates of Fonsecaea sppAntimicrobial Agents and Chemotherapy, 2010
- Pharmacokinetics and Pharmacodynamics of a Novel Triazole, Isavuconazole: Mathematical Modeling, Importance of Tissue Concentrations, and Impact of Immune Status on Antifungal EffectAntimicrobial Agents and Chemotherapy, 2009
- Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida kruseiJournal of Antimicrobial Chemotherapy, 2008
- In Vitro Activity of the New Azole Isavuconazole (BAL4815) Compared with Six Other Antifungal Agents against 162 Cryptococcus neoformans Isolates from CubaAntimicrobial Agents and Chemotherapy, 2008
- In Vitro Antifungal Activities of Isavuconazole (BAL4815), Voriconazole, and Fluconazole against 1,007 Isolates of Zygomycete, Candida , Aspergillus , Fusarium , and Scedosporium SpeciesAntimicrobial Agents and Chemotherapy, 2008
- In Vitro Activities of Isavuconazole and Other Antifungal Agents against Candida Bloodstream IsolatesAntimicrobial Agents and Chemotherapy, 2007